<DOC>
	<DOCNO>NCT00601068</DOCNO>
	<brief_summary>In cooperation Merck &amp; Co , Inc. identify form database 35 patient developed osteochemonecrosis jaw related oral bisphosphonate use . We study trigger , associate medical condition medication , location lesion ( ) , patient outcome .</brief_summary>
	<brief_title>Proposal For The Development Of A Well Defined Database For Patients With Oral Bisphosphonate-Related Osteonecrosis</brief_title>
	<detailed_description>This study observational study , comparative trial . The major outcome represent fraction subject long term heal lesion .</detailed_description>
	<mesh_term>Osteonecrosis</mesh_term>
	<mesh_term>Bisphosphonate-Associated Osteonecrosis Jaw</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Exposed bone oral cavity great 68 week duration unresponsive therapy Pregnant patient Patients less 30 yr age great 90 yrs age Mentally incompetent individual</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>osteonecrosis , jaw , bisphosphonate , fosamax , alendronate</keyword>
</DOC>